Comparative Pharmacology
Head-to-head clinical analysis: CONDYLOX versus PODOFILOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONDYLOX versus PODOFILOX.
CONDYLOX vs PODOFILOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Podofilox, the active ingredient, is an antimitotic agent that binds to microtubule-associated proteins and inhibits microtubule assembly, thereby arresting cell division in metaphase. It also causes necrosis of verrucous tissue by inducing vasoconstriction and ischemia.
Podofilox is a microtubule-disrupting agent that binds to tubulin, inhibiting microtubule polymerization and thereby arresting cell division in metaphase. It also induces necrosis of epithelial cells by interfering with cellular metabolism and DNA synthesis.
Apply 0.5% solution or gel twice daily (morning and evening) for 3 consecutive days, then withhold for 4 days; repeat weekly for up to 4 cycles. Max weekly dose: 0.5 mL or 1.5 g of gel. For condylomata acuminata.
Topical 0.5% solution or gel applied to external genital/perianal warts twice daily for 3 consecutive days, followed by 4 days without treatment; repeat weekly for up to 4 cycles. Maximum application area: 10 cm². Maximum volume per session: 0.5 mL.
None Documented
None Documented
Clinical Note
moderatePodofilox + Digoxin
"Podofilox may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePodofilox + Digitoxin
"Podofilox may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePodofilox + Deslanoside
"Podofilox may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePodofilox + Acetyldigitoxin
"Podofilox may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 2.5 to 5.3 hours; does not accumulate with topical application.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; may be prolonged in hepatic impairment or severe renal dysfunction.
Renal excretion of unchanged drug and glucuronide conjugates; less than 5% excreted in feces.
Primarily renal excretion of metabolites; approximately 70-80% excreted in urine as unchanged drug and glucuronide conjugates, with about 10-20% in feces via biliary elimination.
Category C
Category C
Topical Antimitotic
Topical Antimitotic